Michael Thase, MD
Psychiatry · Philadelphia, PANPI 1982670279
Payments from drug & device makers
Across 466 payments — averaging $4648.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.2M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$340K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130K
- Merck$102K
- H. Lundbeck A S$89K
- Otsuka Pharmaceutical Co., Ltd.$70K
- plus $248K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 141 | $1,186,915 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | $339,995 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $129,739 |
| Merck | 31 | $102,491 |
| H. Lundbeck A S | 28 | $89,119 |
| Otsuka Pharmaceutical Co., Ltd. | 46 | $69,972 |
| Acadia Pharmaceuticals Inc | 14 | $64,333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $48,384 |
| Boehringer Ingelheim International GmbH | 10 | $26,749 |
| Johnson & Johnson | 16 | $21,390 |
| Janssen Scientific Affairs, LLC | 13 | $13,614 |
| Sage Therapeutics, LLC | 13 | $11,837 |
| E.r. Squibb & Sons, L.L.C. | 5 | $11,275 |
| Mylan Inc. | 3 | $10,405 |
| AbbVie(2 entities) | 6 | $7,669 |
| Alkermes, Inc. | 4 | $7,655 |
| Jazz Pharmaceuticals Inc. | 11 | $6,459 |
| Eli Lilly | 3 | $4,713 |
| Pfizer | 1 | $4,533 |
| Luye Pharma (USA) Ltd. | 4 | $3,655 |
| Boehringer Ingelheim | 6 | $2,529 |
| Janssen Global Services, LLC | 1 | $2,500 |
| Otsuka America Pharmaceutical, Inc. | 1 | $44 |
| Upjohn US 1 LLC | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $21 |
How this compares
$2,166,030 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.